Sylvant (siltuximab) / Jazz, BeiGene  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sylvant (siltuximab) / Jazz
NCT01710241: A Study of the Safety and Effectiveness of CNTO 328 When Added to Velcade-Melphalan-Prednisone in Patients With Multiple Myeloma

Active, not recruiting
2
119
US, Europe, RoW
CNTO 328, Velcade, Melphalan, Prednisone
Janssen Research & Development, LLC
Multiple Myeloma
05/14
05/14
NCT03315026: Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Active, not recruiting
2
30
US
Siltuximab, The M.D. Anderson Symptom Inventory (MDASI)
Memorial Sloan Kettering Cancer Center, Janssen Scientific Affairs, LLC
Multiple Myeloma, AL Amyloidosis
10/24
10/24
STARFISH, NCT05684692: Screening Trial for Pain Relief in Schwannomatosis

Recruiting
2
40
US
Siltuximab, Sylvant, Erenumab-Aooe, Aimovig, Siltuximab Matching Placebo, Normal Saline, Erenumab-Aooe Matching Placebo
Massachusetts General Hospital, United States Department of Defense, Recordati Rare Diseases
Schwannomatosis, Schwannomas, Pain, Chronic
03/26
11/27
NCT04191421: Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Completed
1/2
42
US
Siltuximab, Anti-IL-6 Chimeric Monoclonal Antibody, cCLB8, CNTO 328, Sylvant, Spartalizumab, PDR001
Emory University, Novartis, EUSA Pharma, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
04/23
04/23

Download Options